Table 1.
Comparison of characteristics between grade 3 vs. grade 0–2 PIPN patients at the end of chemotherapy.
| Patients with grade 0–2 PIPN (n = 36) | Patients with grade 3 PIPN (n = 12) | p-value | |
|---|---|---|---|
| Age (years), mean ± SD | 51.8 ± 10.7 | 61.8 ± 3.9 | 0.005 |
| Type of gynecological cancer | 0.659 | ||
| Ovarian cancer, n (%) | 29 (81%) | 11 (92%) | |
| Endometrial cancer, n (%) | 7 (19%) | 1 (8%) | |
| BMI (kg/m2), mean ± SD | 22.59 ± 4.15 | 21.21 ± 3.46 | 0.309 |
| BSA (m2), mean ± SD | 1.59 ± 0.16 | 1.52 ± 0.15 | 0.162 |
| Patients with prior exposure to neurotoxic chemotherapy, n (%) | 7 (19%) | 0 (0%) | 0.175 |
| Cumulative dose of paclitaxel, mg/m2, mean ± SD | 993.77 ± 110.32 | 1039.56 ± 23.95 | 0.47 |
| Cumulative dose of carboplatin, mg/m2, mean ± SD | 2496.87 ± 725.81 | 2506.40 ± 2995.61 | 0.949 |
| Combination with bevacizumab, n (%) | 3 (8%) | 0 (0%) | 0.573 |
| Diabetes mellitus, n (%) | 1 (3%) | 1 (8%) | 1.0 |
| EORTC QLQ-CIPN20 scores at pre-chemotherapy, mean ± SD | 19.71 ± 1.23 | 20.25 ± 1.96 | 0.389 |
| EORTC QLQ-CIPN20 scores after two cycles, mean ± SD | 26.03 ± 5.27 | 29 ± 9.19 | 0.455 |
| EORTC QLQ-CIPN20 scores after four cycles, mean ± SD | 28.46 ± 7.81 | 43.45 ± 10.38 | < 0.001 |
| EORTC QLQ-CIPN20 scores after six cycles, mean ± SD | 26 ± 7.73 | 40.36 ± 7.43 | < 0.001 |
| EORTC QLQ-CIPN20 scores after 6 months, mean ± SD | 21.09 ± 3.14 | 28.2 ± 7.36 | 0.009 |
| NCI-CTC grade at 6 months after the end of chemotherapy | < 0.001 | ||
| Grade 0–1 | 31 (86%) | 1 (8%) | |
| Grade 2 | 4 (11%) | 8 (67%) | |
| Grade 3 | 1 (3%) | 3 (25%) |
P < 0.05 are shown in bold.
PIPN, paclitaxel-induced peripheral neuropathy; SD, standard deviation; EORTC QLQ-CIPN20, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20 module; BMI, body mass index; BSA, body surface area; NCI-CTC, National Cancer Institute-Common Toxicity Criteria.